Besides, in patients with alopecia areata, Ritlecitinib led to dose-dependent reductions in T cells and NK cells without affecting CD19+ B cells,46 potentially compromising its efficacy in autoantibody-dominated autoimmune diseases. This evidence concerns the gene CD19 and autoimmune disease.